So far, 2020 has brought several advancements for the Swedish dry powder inhaler company Iconovo. A major stepping stone was the change of CEO in April. With Orest Lastow transitioning from CEO to CTO, to optimize the output of his expertise in the field, Iconovo has recruited Johan Wäborg for the CEO position bringing valuable business development experience to the company’s leadership. BioStock was able to get in touch with Johan Wäborg to learn more about his vision for the company.
Iconovo is a medtech company that offers the development of ready-to-use inhalation products – inhalers in combination with dry powder formulations. The company’s inhalation products are primarily intended for the treatment of asthma and chronic obstructive pulmonary disease (COPD) – two very common respiratory diseases.
Over the years, the company has developed a broad product portfolio including four inhaler platforms, through which Iconovo is able to insert itself into a growing global market. Three of the platforms are already fully developed and available for customization to suit administration of different inhalation powders: ICOres, ICOcap and ICOone. All of these have seen continued progress in terms of updates during the first half of 2020 despite a pandemic disrupting businesses across the globe.